HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic

American Journal of the Medical Sciences

Volumn 315, Issue 1, 1998, Pages 11-16

  Tello, Javier ^a   Soong, Seng Jaw ^a   Hunter, Brenda ^a   Meriwether, Richard ^a   Hook III, Edward W ^a   Mulligan, Mark J ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Jefferson County Department of Health   (United States)

Author keywords

AIDS; HIV; Sexually transmitted diseases; Vaccine acceptance; Vaccine recruitment

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; ATTITUDE; CLINICAL TRIAL; FEMALE; HETEROSEXUALITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; VACCINATION;

EID: 0031964930     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199801000-00003     Document Type: Article

References (22)

1. World Health Organization. Implementation of the Global Strategy for the Prevention and Control of AIDS. New York, World Health Organization; 1992:A45/30:4.
2. Hoth DF, Bolognicsi DP, Corey L, et al. HIV-1 vaccine development: A progress report. Ann Intern Med. 1994; 7:603-11.
3. Piot P, Laga M. Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV-1. BMJ. 1989;298:623-4.
4. Jessamine PG, Plummer FA, Ndiwya Achola, JO, et al. Human immunodeficiency virus, genital ulcers and the male foreskin: Synergism in HIV-1 transmission. Scand J Infect Dis Suppl. 1990; 69:81-6.
5. Figueroa JP, Brathwaite A, Morris J, et al. Rising HFV-1 prevalence among sexually transmitted disease clinic attenders in Jamaica: Traumatic sex and genital ulcers as risk factors. J Acquir Immune Défie Syndr. 1994;3:310-6.
6. Rodrigues J, Mehendale SM, Shepherd ME, et al. The biological and behavioral risk factors for prevalent HIV-1 infection in sexually transmitted diseases clinics in India. Abstract 101. In: Program Book, 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, November 6-10, 1994, Reston, VA.
7. LaForce FM, Marker WH, Fleenor M, et al. Successful strategies in adult immunization. MMWR Morb Mortal Wkly Rep 1991;41:700-9.
8. Moran JS, Peterman TA, Weinstock HS, et al. Prevention of Hepatitis B by immunization of patients in sexually transmitted disease clinics in program and abstracts. Abstract 921. In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 11-14, 1992, Anaheim, CA.
9. Johnson J, Mugerwa R, Mugyenyi P, et al. HIV-1 vaccine acceptability issues in the Ugandan military. Abstract 109. In: Program Book, 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, November 6-10, 1994, Reston, VA.
10. Gross M, Seage G, Mayer K, et al. Willingness of gay/ bisexual men in greater Boston to participate in clinical trials of preventive HTV-1 vaccines. Abstract 96. In: Program Book, 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, November 6-10, 1994, Reston, VA.
11. Koblin B, Taylor P, Stevens C. Project Achieve: A baseline study to prepare for HIV-1 vaccine efficacy trials in New York City (NYC). In: Program Book, 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994:235.
12. Douglas J, Judson F, Parks J, et al. Participation of homosexual/bisexual men in preventive HIV-1 vaccine trials: Baseline attitudes and concerns and predicted behaviors during trials. AIDS Res Hum Retroviruses. 1994;10(suppl 2):S257-60.
13. Vlahov D, Astemborski J, Solomon L, et al. Interest in HIV-1 vaccines among injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses. 1994;10(2):S265-8.
14. Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr. 1995; 10:386-90.
15. Serpelloni G, Vlahov D, Mazzi M, Rezza G. Interest in HIV vaccines among Italian injection drug users. J Acquir Immune Defic Syndr. 1995; 10:206-7.
16. Deschamps MM, Warren DJ, Pape JW. Feasibility and cohort development for HIV-1 vaccine trials in Haiti. AIDS Res Hum Retroviruses. 1994; 10(2)8231-3.
17. Celentano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk population in northern Thailand. AIDS. 1995;9:1079-83.
18. McKirnan D, Buchbinder S, MacQueen K, et al. Stability of risk behaviors for HIV-1 sero-conversion among gay men. In: Program Book, 7th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Reston, VA, November 6-10, 1994:233.
19. Larrat EP, Zierler S, Mayer K. Cocaine use and heterosexual exposure to human immunodeficiency virus. Epidemiology. 1994;5(4):398-403.
20. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. J. Acquir Immune Defic Syndr. 1993;6:1049-56.
21. Nelson KE, Vlahov D, Galai N, Astemborski J, Solomon L. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses. 1994;109(suppl 2):S201-5.
22. Woernle CH, Homes R. Update on HIV/AIDS Epidemic Alabama-Through 1995. Epidemiology Report, vol. X. Birmingham: Alabama Department of Public Health; 1996:3:1-4.